Synthon Hispania S.L. Synthon s.r.o.
PolandAll drugs from this manufacturer
-
The medicinal product is used to treat certain types of cancer: chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma.
Dosage form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine hydrochloride monohydrate 25 mg/vial or 100 mg/vial ATC: L01AA09
-
The medicinal product is used to treat certain types of cancer: chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma.
Dosage form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine hydrochloride monohydrate 26.1 mg or 104.6 mg ATC: L01AA09
-
The medicinal product is used in the treatment of multiple myeloma (a type of bone marrow cancer) in adults over 18 years of age and in the treatment of mantle cell lymphoma (a type of lymph node cancer).
Dosage form: powder for preparation of injection solution
Active substance Dosage bortezomib 1 mg ATC: L01XG01
-
The medicinal product is used to treat multiple myeloma (a type of bone marrow cancer) and mantle cell lymphoma (a type of lymph node cancer) in patients over 18 years of age.
Dosage form: powder for preparation of injection solution
Active substance Dosage bortezomib 3.5 mg ATC: L01XG01
-
The medicinal product is used in the treatment of multiple myeloma (a type of bone marrow cancer) in adults and in the treatment of mantle cell lymphoma (a type of cancer that affects the lymph nodes).
Dosage form: powder for preparation of injection solution
Active substance Dosage bortezomib 1 mg ATC: L01XX32
-
The medicinal product is used in the treatment of multiple myeloma (a type of bone marrow cancer) in adults and in the treatment of mantle cell lymphoma (a type of cancer that affects the lymph nodes).
Dosage form: powder for preparation of injection solution
Active substance Dosage bortezomib 3.5 mg ATC: L01XX32
-
The medicinal product is used to treat multiple myeloma (a type of bone marrow cancer) in adults and to treat mantle cell lymphoma (a type of cancer that affects the lymph nodes).
Dosage form: powder for preparation of injection solution
Active substance Dosage bortezomib 3.5 mg ATC: L01XX32
-
The medicine is used in patients over 18 years of age for the treatment of multiple myeloma (a bone marrow cancer) and mantle cell lymphoma (a type of cancer affecting the lymph nodes).
Dosage form: powder for preparation of injection solution
Active substance Dosage bortezomib 1 mg ATC: L01XX32
-
Xaleba is used to reduce pain and swelling of the joints and muscles in individuals over 16 years of age suffering from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. It also helps in the short-term relief of moderate pain following dental procedures.
Dosage form: tablets, film-coated
Active substance Dosage etoricoxib 30 mg ATC: M01AH05
-
Xaleba is used to reduce pain and swelling of the joints and muscles in individuals over 16 years of age suffering from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. It also helps in the short-term relief of moderate pain following dental surgical procedures.
Dosage form: tablets, film-coated
Active substance Dosage etoricoxib 60 mg ATC: M01AH05
-
Xaleba is used to reduce pain and swelling of the joints and muscles in individuals over 16 years of age suffering from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. It also helps in the short-term relief of moderate pain following dental surgical procedures.
Dosage form: tablets, film-coated
Active substance Dosage etoricoxib 90 mg ATC: M01AH05
-
The medicine is used to reduce pain and inflammation of the joints and muscles in individuals over 16 years of age suffering from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. It also helps in the short-term relief of moderate pain following dental surgical procedures.
Dosage form: tablets, film-coated
Active substance Dosage etoricoxib 120 mg ATC: M01AH05